S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
DIS   146.93 (-0.98%)
Log in

Miragen Therapeutics Stock Price, Forecast & Analysis (NASDAQ:MGEN)

$0.63
-0.01 (-1.56 %)
(As of 11/20/2019 04:00 PM ET)
Today's Range
$0.62
Now: $0.63
$0.66
50-Day Range
$0.60
MA: $0.75
$0.99
52-Week Range
$0.57
Now: $0.63
$4.96
Volume269,233 shs
Average Volume211,175 shs
Market Capitalization$20.03 million
P/E RatioN/A
Dividend YieldN/A
Beta1.37
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGEN
CUSIPN/A
Phone720-643-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.39 million
Book Value$1.66 per share

Profitability

Net Income$-32,700,000.00
Net Margins-1,037.02%

Miscellaneous

Employees77
Market Cap$20.03 million
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable

Receive MGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.


Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions

What is Miragen Therapeutics' stock symbol?

Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."

How were Miragen Therapeutics' earnings last quarter?

Miragen Therapeutics Inc (NASDAQ:MGEN) posted its earnings results on Thursday, November, 7th. The medical research company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.06. The medical research company earned $0.70 million during the quarter, compared to the consensus estimate of $1.67 million. Miragen Therapeutics had a negative return on equity of 100.38% and a negative net margin of 1,037.02%. View Miragen Therapeutics' Earnings History.

When is Miragen Therapeutics' next earnings date?

Miragen Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Miragen Therapeutics.

What price target have analysts set for MGEN?

4 equities research analysts have issued 1 year price targets for Miragen Therapeutics' shares. Their forecasts range from $3.00 to $24.00. On average, they anticipate Miragen Therapeutics' share price to reach $15.17 in the next twelve months. This suggests a possible upside of 2,307.4% from the stock's current price. View Analyst Price Targets for Miragen Therapeutics.

What is the consensus analysts' recommendation for Miragen Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Miragen Therapeutics.

Has Miragen Therapeutics been receiving favorable news coverage?

Headlines about MGEN stock have trended somewhat positive on Wednesday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Miragen Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Miragen Therapeutics.

Are investors shorting Miragen Therapeutics?

Miragen Therapeutics saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 843,000 shares, an increase of 22.4% from the September 15th total of 688,700 shares. Based on an average trading volume of 251,300 shares, the days-to-cover ratio is currently 3.4 days. Approximately 3.4% of the shares of the stock are short sold. View Miragen Therapeutics' Current Options Chain.

Who are some of Miragen Therapeutics' key competitors?

What other stocks do shareholders of Miragen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Miragen Therapeutics investors own include Alibaba Group (BABA), Opko Health (OPK), Bellicum Pharmaceuticals (BLCM), Novavax (NVAX), AbbVie (ABBV), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Tetraphase Pharmaceuticals (TTPH), Genocea Biosciences (GNCA) and Amarin (AMRN).

Who are Miragen Therapeutics' key executives?

Miragen Therapeutics' management team includes the folowing people:
  • Dr. William Stuart Marshall Ph.D., Co-Founder, Pres, CEO & Director (Age 55)
  • Mr. Adam Scott Levy, Chief Bus. Officer (Age 41)
  • Dr. Paul D. Rubin, Exec. VP of R&D (Age 65)
  • Eric N. Olson, Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 74)

How do I buy shares of Miragen Therapeutics?

Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Miragen Therapeutics' stock price today?

One share of MGEN stock can currently be purchased for approximately $0.63.

How big of a company is Miragen Therapeutics?

Miragen Therapeutics has a market capitalization of $20.03 million and generates $8.39 million in revenue each year. The medical research company earns $-32,700,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. Miragen Therapeutics employs 77 workers across the globe.View Additional Information About Miragen Therapeutics.

What is Miragen Therapeutics' official website?

The official website for Miragen Therapeutics is http://www.signalgenetics.com/.

How can I contact Miragen Therapeutics?

Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]


MarketBeat Community Rating for Miragen Therapeutics (NASDAQ MGEN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  395
MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote "Outperform" if you believe MGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel